vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and JOINT Corp (JYNT). Click either name above to swap in a different company.
JOINT Corp is the larger business by last-quarter revenue ($15.2M vs $15.0M, roughly 1.0× CHAMPIONS ONCOLOGY, INC.). JOINT Corp runs the higher net margin — 6.5% vs 1.8%, a 4.8% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs 3.1%). JOINT Corp produced more free cash flow last quarter ($334.7K vs $-2.0M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -28.6%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
CSBR vs JYNT — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $15.2M |
| Net Profit | $268.0K | $991.1K |
| Gross Margin | 51.7% | 81.4% |
| Operating Margin | 1.2% | 4.9% |
| Net Margin | 1.8% | 6.5% |
| Revenue YoY | 11.5% | 3.1% |
| Net Profit YoY | -63.2% | 5510.5% |
| EPS (diluted) | $0.02 | $0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $15.2M | ||
| Q3 25 | $14.0M | $13.4M | ||
| Q2 25 | $12.4M | $13.3M | ||
| Q1 25 | $17.0M | $13.1M | ||
| Q4 24 | $13.5M | $14.7M | ||
| Q3 24 | $14.1M | $30.2M | ||
| Q2 24 | $14.0M | $30.3M | ||
| Q1 24 | $12.0M | $29.7M |
| Q4 25 | $268.0K | $991.1K | ||
| Q3 25 | $-436.0K | $855.0K | ||
| Q2 25 | $-1.8M | $93.4K | ||
| Q1 25 | $4.5M | $967.8K | ||
| Q4 24 | $728.0K | $17.7K | ||
| Q3 24 | $1.3M | $-3.2M | ||
| Q2 24 | $-109.0K | $-3.6M | ||
| Q1 24 | $-2.5M | $947.0K |
| Q4 25 | 51.7% | 81.4% | ||
| Q3 25 | 42.9% | 80.1% | ||
| Q2 25 | 41.1% | 79.1% | ||
| Q1 25 | 61.2% | 77.3% | ||
| Q4 24 | 44.9% | 78.4% | ||
| Q3 24 | 49.7% | 90.7% | ||
| Q2 24 | 48.2% | 90.7% | ||
| Q1 24 | 34.7% | 90.9% |
| Q4 25 | 1.2% | 4.9% | ||
| Q3 25 | -3.8% | 1.2% | ||
| Q2 25 | -16.2% | -8.6% | ||
| Q1 25 | 26.4% | -5.2% | ||
| Q4 24 | 5.4% | 5.5% | ||
| Q3 24 | 9.5% | -1.6% | ||
| Q2 24 | -1.9% | -5.9% | ||
| Q1 24 | -21.4% | -1.4% |
| Q4 25 | 1.8% | 6.5% | ||
| Q3 25 | -3.1% | 6.4% | ||
| Q2 25 | -14.9% | 0.7% | ||
| Q1 25 | 26.4% | 7.4% | ||
| Q4 24 | 5.4% | 0.1% | ||
| Q3 24 | 9.3% | -10.5% | ||
| Q2 24 | -0.8% | -11.9% | ||
| Q1 24 | -21.1% | 3.2% |
| Q4 25 | $0.02 | $0.06 | ||
| Q3 25 | $-0.03 | $0.06 | ||
| Q2 25 | $-0.12 | $0.01 | ||
| Q1 25 | $0.31 | $0.06 | ||
| Q4 24 | $0.05 | $0.01 | ||
| Q3 24 | $0.09 | $-0.21 | ||
| Q2 24 | $-0.01 | $-0.24 | ||
| Q1 24 | $-0.19 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $23.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $15.1M |
| Total Assets | $30.2M | $61.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $23.6M | ||
| Q3 25 | $10.3M | $29.7M | ||
| Q2 25 | $9.8M | $29.8M | ||
| Q1 25 | $3.2M | $21.9M | ||
| Q4 24 | $2.8M | $25.1M | ||
| Q3 24 | $2.9M | $20.7M | ||
| Q2 24 | $2.6M | $17.5M | ||
| Q1 24 | $4.5M | $18.7M |
| Q4 25 | $4.2M | $15.1M | ||
| Q3 25 | $3.5M | $22.7M | ||
| Q2 25 | $3.8M | $23.2M | ||
| Q1 25 | $5.5M | $22.8M | ||
| Q4 24 | $681.0K | $20.7M | ||
| Q3 24 | $-332.0K | $20.5M | ||
| Q2 24 | $-1.9M | $23.2M | ||
| Q1 24 | $-2.1M | $26.2M |
| Q4 25 | $30.2M | $61.0M | ||
| Q3 25 | $30.5M | $69.4M | ||
| Q2 25 | $32.3M | $73.2M | ||
| Q1 25 | $30.6M | $80.1M | ||
| Q4 24 | $25.2M | $83.2M | ||
| Q3 24 | $24.9M | $79.6M | ||
| Q2 24 | $26.1M | $82.4M | ||
| Q1 24 | $26.8M | $85.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $1.8M |
| Free Cash FlowOCF − Capex | $-2.0M | $334.7K |
| FCF MarginFCF / Revenue | -13.1% | 2.2% |
| Capex IntensityCapex / Revenue | 1.6% | 9.9% |
| Cash ConversionOCF / Net Profit | -6.47× | 1.86× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $-1.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $1.8M | ||
| Q3 25 | $600.0K | $1.8M | ||
| Q2 25 | $6.9M | $868.6K | ||
| Q1 25 | $490.0K | $-3.7M | ||
| Q4 24 | $-283.0K | $9.4M | ||
| Q3 24 | $311.0K | $3.4M | ||
| Q2 24 | $-1.8M | $-973.5K | ||
| Q1 24 | $-919.0K | $2.8M |
| Q4 25 | $-2.0M | $334.7K | ||
| Q3 25 | $554.0K | $1.5M | ||
| Q2 25 | $6.6M | $363.6K | ||
| Q1 25 | $448.0K | $-4.0M | ||
| Q4 24 | $-377.0K | $8.2M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | $-1.8M | $-1.2M | ||
| Q1 24 | $-1.0M | $2.4M |
| Q4 25 | -13.1% | 2.2% | ||
| Q3 25 | 4.0% | 10.9% | ||
| Q2 25 | 53.5% | 2.7% | ||
| Q1 25 | 2.6% | -30.8% | ||
| Q4 24 | -2.8% | 55.9% | ||
| Q3 24 | — | 10.6% | ||
| Q2 24 | -13.0% | -4.1% | ||
| Q1 24 | -8.4% | 8.1% |
| Q4 25 | 1.6% | 9.9% | ||
| Q3 25 | 0.3% | 2.4% | ||
| Q2 25 | 2.0% | 3.8% | ||
| Q1 25 | 0.2% | 2.5% | ||
| Q4 24 | 0.7% | 8.1% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.0% | 0.9% | ||
| Q1 24 | 0.8% | 1.3% |
| Q4 25 | -6.47× | 1.86× | ||
| Q3 25 | — | 2.07× | ||
| Q2 25 | — | 9.30× | ||
| Q1 25 | 0.11× | -3.82× | ||
| Q4 24 | -0.39× | 532.98× | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
